Alex Azar And The Return Of Republican-Style Price Negotiation

The nomination of a former drug industry executive to run HHS is obviously good news for the biopharma sector, but it does not mean that HHS will do nothing about drug prices. On the contrary, it may make some high-profile action against pricing outliers all but inevitable.

Low-Risk-Dial_513089503_1200

Alex Azar appears to be on a fast track to a relatively smooth confirmation as secretary of the US Department of Health and Human Services (HHS) – but the biopharma industry should expect drug pricing to be the subject of extra attention along the way.

The Senate Health, Education, Labor & Pensions Committee is set to kick off the confirmation process with a hearing Nov....

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Pricing Debate

More from Market Access